Sloan Sheldon
SEC CIK 2038798 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | Chief Medical Off | 8,334 | — | $7.35M | 8 | 2026-04-01 | 2026-07-01 |
Most active insiders at SYRE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | Dir | — | $399.66M |
| 2 | Turtle Cameron | CEO, Dir | — | $9.99M |
| 3 | HENDERSON MICHAEL THOMAS | Dir | — | $7.95M |
| 4 | Sloan Sheldon | Chief Medical Off | — | $7.35M |
| 5 | Burrows Scott L | CFO | — | $6.86M |
| 6 | King-Jones Heidy | See Remarks | — | $2.48M |
| 7 | Albers Jeffrey W. | Dir | — | $2.40M |
Transactions 8
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | M - OptEx | $27.46 | +8,334 | 8,334 | New | +$228.9K |
| DMT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $87.70 | -8,334 | 0 | -100% | -$730.9K |
| DT | 2026-06-03 21:32 | 2026-06-03 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | M - OptEx | $27.46 | +8,333 | 8,333 | New | +$228.8K |
| DT | 2026-06-03 21:32 | 2026-06-03 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $75.00 | -8,333 | 0 | -100% | -$625.0K |
| DT | 2026-05-01 21:34 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | M - OptEx | $27.46 | +78.3K | 78.3K | New | +$2.15M |
| DMT | 2026-05-01 21:34 | 2026-05-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $71.50 | -78.3K | 0 | -100% | -$5.60M |
| DT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | M - OptEx | $21.66 | +7,958 | 7,958 | New | +$172.4K |
| DT | 2026-04-03 21:30 | 2026-04-01 | SYRE | Spyre Therapeutics, Inc. | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $50.00 | -7,958 | 0 | -100% | -$397.9K |
Purchase Sale Sale after option exercise All abbreviations